BELIEVE Trial: Bimagrumab + Semaglutide Achieves 22.1% Weight Loss With 92.8% From Fat Mass
Full analysis of the BELIEVE Phase 2b trial: bimagrumab + semaglutide combination produces 22.1% weight loss, 58.2% VAT reduction, and near-complete muscle preservation.
The BELIEVE trial (NCT05616013), published in Nature Medicine in March 2026, represents a paradigm shift in obesity pharmacotherapy: the first demonstration that aggressive fat loss and muscle preservation can be achieved simultaneously through combination drug therapy.
Trial Design
BELIEVE was a Phase 2b randomized, double-blind, placebo-controlled, multicenter study. 507 adults with obesity (BMI ≥30 or ≥27 with complication) were randomized across nine arms testing IV bimagrumab (10 or 30 mg/kg q12 weeks) and SC semaglutide (1.0 or 2.4 mg weekly) alone and in combination over 48 weeks, with open-label extension through week 72.
Key Results
| Arm | Weight Loss | % From Fat | Lean Mass Change | VAT Reduction |
|---|---|---|---|---|
| Placebo | -1.3% | — | — | — |
| Bimagrumab 30mg alone | -10.8% | ~100% | +2.5% | — |
| Semaglutide 2.4mg alone | -15.7% | 71.8% | -7.4% | -35.8% |
| Bima 30mg + Sema 2.4mg | -22.1% | 92.8% | -2.9% | -58.2% |
Mechanism of Complementarity
Bimagrumab is a monoclonal antibody targeting type II activin receptors, blocking activin A and myostatin signaling. This produces two simultaneous effects: promotion of skeletal muscle growth/maintenance (anti-myostatin) and enhanced adipocyte lipid mobilization. Combined with semaglutide's central appetite suppression, the result is a pharmacologically elegant division of labor — semaglutide reduces caloric intake, bimagrumab redirects the body composition outcome toward fat loss.
The complementarity extends to adiposity measures: combination therapy reduced total fat mass by 45.7% (vs. 27.8% sema alone) and visceral adipose tissue by 58.2% (vs. 35.8% sema alone). This visceral fat selectivity has direct implications for cardiometabolic risk reduction.
Safety
Adverse events were mechanism-consistent: muscle spasms and acne with bimagrumab (activin pathway), GI intolerance with semaglutide (GLP-1 class effect). Discontinuations were highest in bimagrumab monotherapy arms. No mortality events. Combination safety was consistent with known profiles for both agents.
Regulatory and Commercial Implications
Eli Lilly acquired Versanis Bio (bimagrumab developer) for $1.9 billion. Studies of bimagrumab + tirzepatide are underway. If Phase 3 confirms the BELIEVE signal, bimagrumab could become the standard adjunct to GLP-1/GIP agonist therapy for patients concerned about body composition quality.
The broader implication: the "muscle loss" criticism of GLP-1 therapy has a pharmacological solution. BELIEVE proves the concept. The remaining questions are dose optimization, long-term safety, and whether the combination's additional cost is justified by improved outcomes.
The Bottom Line
BELIEVE establishes that the combination of activin receptor blockade (bimagrumab) and GLP-1 agonism (semaglutide) can achieve 22% weight loss with 93% from fat mass — virtually eliminating the lean mass loss concern. The 58% visceral fat reduction exceeds anything achieved by semaglutide monotherapy. This combination framework is likely the next major advance in obesity pharmacotherapy after retatrutide.
Sources
- Heymsfield SB et al. "Bimagrumab plus semaglutide for obesity: a randomized phase 2 trial." Nature Medicine. 2026. DOI:10.1038/s41591-026-04204-0
- ADA. "New GLP-1 Therapies Enhance Quality of Weight Loss." 85th Scientific Sessions. 2026.
- Pharmacy Times. "Bimagrumab-Semaglutide Combination." May 22, 2026.
- HCPLive. "BELIEVE: Bimagrumab/Semaglutide Combo." May 2026.
- ConscienHealth. "Striking Results with Bimagrumab and Semaglutide." March 2026.